A prospective, multicentre, open label, exploratory study to investiga
A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg Assay Panel and the B-Cell /Antibody response panel to predict the clinical effect of Octagam 5% in subjects with relapsing/remitting (RR) multiple sclerosis (MS)
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Immunoglobulin
What it measured
Main measures
Heidelberg Assay Panel
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion: ·Subjects aged ≥ 18 years. Exclusion: Subjects who have received treatment with immunoglobulins for any reason previously.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To investigate whether any parameters of the HAP correlate with the clinical effect observed following Octagam 5% treatment in subjects with RR MS.
Loading reviews and guidelines…
History
Started
Sept 2008